Insomnia is associated with an increased risk of type 2 diabetes in the clinical setting

Erin S LeBlanc, Ning X Smith, Gregory A Nichols, Michael J Allison, Gregory N Clarke, Erin S LeBlanc, Ning X Smith, Gregory A Nichols, Michael J Allison, Gregory N Clarke

Abstract

Objective: To determine the possible association between insomnia and risk of type 2 diabetes mellitus (T2DM) in the naturalistic clinical setting.

Research design and methods: We conducted a retrospective cohort study to examine the risk of developing T2DM among patients with pre-diabetes with and without insomnia. Participants with pre-diabetes (identified by a physician or via two laboratory tests) between January 1, 2007 and December 31, 2015 and without sleep apnea were followed until December 31, 2016. Patients were determined to have T2DM when two of the following occurred within a 2-year window: physician-entered outpatient T2DM diagnosis (International Classification of Diseases [ICD]-9 250.00; ICD-10 E11), dispensing of an antihyperglycemia agent, and hemoglobin A1c (A1c) >6.5% (48 mmol/mol) or fasting plasma glucose (FPG) >125 mg/dL. One hospital inpatient stay with an associated T2DM diagnosis was also sufficient for classification of T2DM.

Results: Our cohort consisted of 81 233 persons with pre-diabetes, 24 146 (29.7%) of whom had insomnia at some point during the 4.3-year average observation period. After adjustment for traditional risk factors, those with insomnia were 28% more likely to develop T2DM than those without insomnia (HR 1.28; 95% CI 1.24 to 1.33). The estimate was essentially unchanged after adjusting for baseline A1c level (HR 1.32; 95% CI 1.25 to 1.40) or FPG (HR 1.28; 95% CI 1.23 to 1.33).

Conclusions: Insomnia imparts an increased risk of T2DM comparable with that conferred by traditional risk factors (eg, overweight, non-white race, cardiovascular risk factors). This association could have clinical importance because it suggests a new potentially modifiable risk factor that could be targeted to prevent diabetes.

Keywords: prevention; sleep disorder(s); type 2 diabetes.

Conflict of interest statement

Competing interests: ESL has had unrelated funding from Merck in the last years. GAN has unrelated grant funding from Boehringer-Ingelheim, Merck & Co, Sanofi, Janssen Pharmaceuticals and Amarin.

References

    1. Centers for Disease Control and Prevention Diabetes report card 2014. Atlanta GA: Centers for Disease Control and Prevention US Dept of Health and Human Services, 2015.
    1. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. The Lancet 1999;354:1435–9. 10.1016/S0140-6736(99)01376-8
    1. van Leeuwen WMA, Hublin C, Sallinen M, et al. . Prolonged sleep restriction affects glucose metabolism in healthy young men. Int J Endocrinol 2010;2010:1–7. 10.1155/2010/108641
    1. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010;137:95–101. 10.1378/chest.09-0791
    1. Buxton OM, Pavlova M, Reid EW, et al. . Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes 2010;59:2126–33. 10.2337/db09-0699
    1. Nedeltcheva AV, Kessler L, Imperial J, et al. . Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. J Clin Endocrinol Metab 2009;94:3242–50. 10.1210/jc.2009-0483
    1. Benedict C, Hallschmid M, Lassen A, et al. . Acute sleep deprivation reduces energy expenditure in healthy men. Am J Clin Nutr 2011;93:1229–36. 10.3945/ajcn.110.006460
    1. Cedernaes J, Lampola L, Axelsson EK, et al. . A single night of partial sleep loss impairs fasting insulin sensitivity but does not affect cephalic phase insulin release in young men. J Sleep Res 2016;25:5–10. 10.1111/jsr.12340
    1. Rao MN, Neylan TC, Grunfeld C, et al. . Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metab 2015;100:1664–71. 10.1210/jc.2014-3911
    1. St-Onge M-P, Grandner MA, Brown D, et al. . Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American heart association. Circulation 2016;134:e367–86. 10.1161/CIR.0000000000000444
    1. Gale JE, Cox HI, Qian J, et al. . Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms 2011;26:423–33. 10.1177/0748730411416341
    1. Spiegel K, Leproult R, L'hermite-Balériaux M, et al. . Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 2004;89:5762–71. 10.1210/jc.2004-1003
    1. Irwin M, Clark C, Kennedy B, et al. . Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun 2003;17:365–72. 10.1016/S0889-1591(03)00031-X
    1. Leproult R, Copinschi G, Buxton O, et al. . Sleep loss results in an elevation of cortisol levels the next evening. Sleep 1997;20:865–70.
    1. Bromley LE, Booth JN, Kilkus JM, et al. . Sleep restriction decreases the physical activity of adults at risk for type 2 diabetes. Sleep 2012;35:977–84. 10.5665/sleep.1964
    1. Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity 2008;16:643–53. 10.1038/oby.2007.118
    1. Nichols GA, Schroeder EB, Karter AJ, et al. . Trends in diabetes incidence among 7 million insured adults, 2006-2011: the SUPREME-DM project. Am J Epidemiol 2015;181:32–9. 10.1093/aje/kwu255
    1. Nichols GA, Brown JB. Validating the Framingham offspring study equations for predicting incident diabetes mellitus. Am J Manag Care 2008;14:574–80.
    1. Leblanc ES, O'Connor E, Whitlock EP, et al. . Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med 2011;155:434–47. 10.7326/0003-4819-155-7-201110040-00006
    1. Riemann D, Baglioni C, Bassetti C, et al. . European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26:675–700. 10.1111/jsr.12594
    1. Brasure M, Fuchs E, MacDonald R, et al. . Psychological and behavioral interventions for managing insomnia disorder: an evidence report for a clinical practice guideline by the American college of physicians. Ann Intern Med 2016;165:113–24. 10.7326/M15-1782
    1. Edinger JD, Wohlgemuth WK, Radtke RA, et al. . Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial. Sleep 2007;30:203–12. 10.1093/sleep/30.2.203
    1. Kowall B, Lehnich AT, Strucksberg KH, et al. . Associations among sleep disturbances, nocturnal sleep duration, daytime napping, and incident prediabetes and type 2 diabetes: the Heinz Nixdorf recall study. Sleep Med 2016;21:35–41. 10.1016/j.sleep.2015.12.017
    1. Champaneri S, Xu X, Carnethon MR, et al. . Diurnal salivary cortisol is associated with body mass index and waist circumference: the multiethnic study of atherosclerosis. Obesity 2013;21:E56–63. 10.1002/oby.20047
    1. Xu H, Barnes GT, Yang Q, et al. . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–30. 10.1172/JCI200319451
    1. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Archivum Immunologiae et Therapiae Experimentalis 2013;61:119–25. 10.1007/s00005-012-0210-1
    1. Zinman B, Hanley AJ, Harris SB, et al. . Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272–8. 10.1210/jcem.84.1.5405
    1. Ting L, Malhotra A. Disorders of sleep: an overview. Primary Care: Clinics in Office Practice 2005;32:305–18. 10.1016/j.pop.2005.02.004
    1. Tancredi M, Rosengren A, Svensson AM, et al. . Excess mortality among Persons with Type 2 diabetes. N Engl J Med 2015;373:1720–32. 10.1056/NEJMoa1504347

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel